Latest Breaking News On - மனிதன் புற்றுநோயியல் - Page 2 : comparemela.com
LLNL earn A grade in OPCW biomedical proficiency test
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Where are the rock stars of climatology?
scienceblogs.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblogs.com Daily Mail and Mail on Sunday newspapers.
49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, demonstrating durable improvement in survival with first-line Opdivo (nivolumab) plus Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with Opdivo plus Yervoy (95% CI: 38.2-NR), the longest reported median OS in a Phase 3 advanced melanoma trial, 36.9 months with
Summary
Neuro-oncologist Ingo Mellinghoff first became intrigued by scientific questions regarding brain tumors while working in the lab of physician-scientist Charles Sawyers before both came to MSK. Now, Dr. Mellinghoff leads MSK’s Department of Neurology as it deploys innovative technologies to understand how these cancers develop and progress.
When neuro-oncologist Ingo Mellinghoff was named Chair of Memorial Sloan Kettering’s Department of Neurology in October 2020, it marked the culmination of a career devoted to studying how cancer affects the brain. Dr. Mellinghoff previously served as Chief of the MSK Brain Tumor Service and Vice Chair of Research in the Department of Neurology as well as its Interim Chair. His research laboratory in the Human Oncology and Pathogenesis Program (HOPP) focuses on how faulty signals in brain cells can lead to the development and growth of brain tumors.
Summary
New research from Memorial Sloan Kettering scientists suggests that a way to improve immunotherapy is by altering immune cells’ access to sugar.
Cancer cells and immune cells share something in common: They both love sugar.
Sugar is an important nutrient. All cells use sugar as a vital source of energy and building blocks. For immune cells, gobbling up sugar is a good thing, since it means getting enough nutrients to grow and divide for stronger immune responses. But cancer cells use sugar for more nefarious ends.
So, what happens when tumor cells and immune cells battle for access to the same supply of sugar? That’s the central question that Memorial Sloan Kettering researchers Taha Merghoub, Jedd Wolchok, and Roberta Zappasodi explore in a new study published February 15 in the journal
vimarsana © 2020. All Rights Reserved.